Table 2.
The incidence of ICI-induced AEs or flare of preexisting diseases in patients with prior AEs or preexisting autoimmune diseases.
| Study | Cancer | ICIs | Ipi-induced immune-related AEs |
Preexisting autoimmune diseases |
||
|---|---|---|---|---|---|---|
| Colitis | Non-colitis | Crohn's disease or ulcerative colitis | Non-GI disorders | |||
| Johnson et al 201644 | Melanoma | CTLA4 | – | – | 33.3% (2/6, 1 flare and 1 colitis) | 25.0% (4/24) |
| Gutzmer et al 201742 | Melanoma | PD-1 | 0 (0/11) | 0 (0/11) | 100.0% (1/1, 1 colitis) | 0 (0/18) |
| Menzies et al 201743 | Melanoma | PD-1 | 2.1% (1/47) | 40.0% (8/20) | 0 (0/6) | ≥2.2% (≥1/46) |
AE: adverse event; ICI: immune-checkpoint inhibitor; Ipi: ipilimumab; GI: gastrointestinal; CTLA4: cytotoxic T lymphocyte-associated antigen 4; PD-1: programmed death-1.